Renal function estimation and carboplatin dosing in children
Author Information
Author(s): Chinnaswamy G, Cole M, Boddy A V, Keir M, Price L, Parry A, English M, Veal G J
Primary Institution: Northern Institute for Cancer Research, University of Newcastle upon Tyne
Hypothesis
How do current practices of measuring GFR in paediatric oncology centres impact carboplatin dosing?
Conclusion
The study highlights significant variations in renal function measurement practices across clinical centres, which can lead to substantial differences in carboplatin dosing for children with cancer.
Supporting Evidence
- Renal function-based carboplatin dosing is routinely used in paediatric oncology.
- Current practices of measuring GFR vary significantly across clinical centres.
- Implementation of BNMS guidelines could lead to a decrease in carboplatin dose for many patients.
Takeaway
Doctors need to measure kidney function accurately to give the right amount of medicine to kids with cancer, and this study shows that different hospitals do it differently.
Methodology
A questionnaire survey was conducted across 21 CCLG paediatric oncology centres to assess GFR measurement practices, and retrospective data from 337 GFR tests were analyzed to evaluate the impact on carboplatin dosing.
Potential Biases
Variability in GFR measurement methods could lead to inconsistent carboplatin dosing across different centres.
Limitations
The study did not prospectively evaluate the clinical outcomes of the changes in carboplatin dosing.
Participant Demographics
The study involved 178 children with a median age of 12.4 years and a median weight of 36.6 kg.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website